Rheumatoid arthritis—common origins, divergent mechanisms

EM Gravallese, GS Firestein - New England Journal of Medicine, 2023 - Mass Medical Soc
Rheumatoid Arthritis — Common Origins, Divergent Mechanisms | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?

R Pofi, G Caratti, DW Ray, JW Tomlinson - Endocrine Reviews, 2023 - academic.oup.com
It is estimated that 2% to 3% of the population are currently prescribed systemic or topical
glucocorticoid treatment. The potent anti-inflammatory action of glucocorticoids to deliver …

Risk of COVID‐19 in rheumatoid arthritis: a National Veterans Affairs matched cohort study in at‐risk individuals

BR England, P Roul, Y Yang, AC Kalil… - Arthritis & …, 2021 - Wiley Online Library
Objective Rheumatoid arthritis (RA) and its treatments are associated with an increased risk
of infection, but it remains unclear whether these factors have an impact on the risk or …

[HTML][HTML] EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update

B Hellmich, B Sanchez-Alamo, JH Schirmer… - Annals of the …, 2024 - ard.bmj.com
Background Since the publication of the EULAR recommendations for the management of
antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several …

Waiting for JAK inhibitor safety data

TW Kragstrup, B Glintborg, AL Svensson… - RMD open, 2022 - rmdopen.bmj.com
The US Food and Drug Administration (FDA) has recently added a new 'black box
warning'on all currently approved Janus kinase (JAK) inhibitors indicated for the treatment of …

Excess uric acid induces gouty nephropathy through crystal formation: a review of recent insights

Y Mei, B Dong, Z Geng, L Xu - Frontiers in Endocrinology, 2022 - frontiersin.org
Uric acid (UA) is the final product of purine metabolism in the human body, and impaired
purine metabolism can increase the uric acid in serum, finally resulting in hyperuricemia …

Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of …

SA Bergstra, A Sepriano, A Kerschbaumer… - Annals of the …, 2023 - ard.bmj.com
This systematic literature review (SLR) regarding the efficacy, duration of use and safety of
glucocorticoids (GCs), was performed to inform the 2022 update of the EULAR …

[HTML][HTML] Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной …

ЕЛ Насонов, АМ Лила, ВИ Мазуров… - Научно …, 2021 - cyberleninka.ru
В середине 2021 года инфекция SARS-CoV-2 (Severe Acute Respiratory coronavirus 2),
вызвавшая пандемию коронавирусной болезни 2019 (coronavirus disease, COVID-19) …

Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities

LK Stamp, H Farquhar, HL Pisaniello… - Nature Reviews …, 2021 - nature.com
Gout and chronic kidney disease (CKD) frequently coexist, but quality evidence to guide
gout management in people with CKD is lacking. Use of urate-lowering therapy (ULT) in the …

Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis

AJ Ocon, G Reed, DA Pappas, JR Curtis… - Annals of the rheumatic …, 2021 - ard.bmj.com
Objectives Rheumatoid arthritis (RA), along with glucocorticoid use, is associated with
cardiovascular disease. Cardiovascular safety of glucocorticoids in RA is controversial and …